Dr. Daniel Song has worked in pharmaceutical industry for over 25 years.  His working experience includes R&D, patent infringement, manufacturing, quality, supply chain, regulatory, Business development, and management. Dr. Daniel Song directly supported 8 NDA/BLA approvals and 50+ IND approvals globally for small molecule, biological, and CAR-T products.  On behalf of J&J, he was deeply involved in J&J-Legend BCMA CAR-T co-development project and led team to obtain first CAR-T IND approval in China and US in 2018.

Before co-founding UTC Therapeutics Inc., Dr. Daniel Song was a Deputy General Manager at Hrain Biotechnology Co., Ltd..  Before joining Hrain, He was a Director in Global Regulatory affairs at J&J and served in leadership team of J&J Asia Pacific Manufacturing Group. Dr. Daniel Song had also worked as a Senior Principal Scientist at Pfizer Global R&D and Global Manufacturing for 16 years, where he founded Pfizer Excipient Chemistry Network as a Pfizer global function team.

Dr. Zhao brings UTC Therapeutics Inc. over 20 years of distinguished experiences in T cell immunotherapy with a renowned list of accomplishments, including the successful development of multiple novel CAR-T pipelines and conducting leading research that generated over 50 publications and over 170 patent filings.

Before co-founding UTC Therapeutics, Dr. Zhao was the Director of T Cell Engineering Lab at Center for Cellular Therrapy Institute, and an Adjunct Associate Professor of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania. Dr. Zhao's research in cancer immunotherapies has led to remarkable advancements, such as the creation of Kymriah and Yescarta, known for their capability to cure hematological cancers. Additionally, Dr. Zhao discovered the power of mRNA CAR-T treatments and was the first to utilize CRISPR/CAS9 techniques in patient treatment in the U.S. Dr, Zhao also led multiple cutting-edge clinical research projects in Steven Rosenberg's lab at National Institutes of Health from 2003 to 2009.

Dr. Liu co-founded UTC Therapeutics Inc. with over 10 years of experience in T cell immunotherapy with an exemplary track records of conducting ground-breaking research, achieving over 20 publications and 11 patents. Her profound research and commitment to science have advanced translational research resulting in the first U.S. clinical trial to apply CRISPR/CAS9 techniques.

Before co-founding UTC Therapeutics, Dr. Liu served as the Deputy Director of the T Cell Engineering Lab in the Center for Cellular Immunotherapies at the University of Pennsylvania (Upenn). At UPenn, she deeply involved several translational clinical research pipelines regarding treatments for cancers and HIV.